FDA staff and scientists were basing the recommendations on the evidence, and that’s how it’s supposed to be,” said one of ...

Both sides of the aisle were heated about the issue of women being coerced into medicated abortion during a nearly ...

The Senate’s health committee convened its first hearing of the year on the efficacy of the chemical abortion drug ...

A study of more than 5,000 pages of agency documents on mifepristone over 12 years found that agency leaders almost always ...

In 2023, the FDA amended the risk evaluation and mitigation strategies (REMS) program for mifepristone, eliminating the ...

The Senate Health, Education, Labor, and Pensions Committee, chaired by Sen. Bill Cassidy, R-Louisiana, held a hearing about ...

A new review suggests that the FDA usually followed the science, not politics, when making key decisions about mifepristone.

The FDA has taken a cautious and scientific evidence-based approach to regulating mifepristone (Mifeprex) over the years, ...

The Senate Committee on Health, Education, Labor and Pensions (HELP) is holding a hearing Wednesday morning focused on ...

The Trump administration faces scrutiny from some pro-lifers over the Food and Drug Administration's recent approval of a new ...

"It's pretty stunning to watch these Republicans talk about this with a straight face,” Murray said in an interview.